Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 20Unknown 10Recruiting 5Terminated 3Active not recruiting 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

zilucoplan 1rozanolixizumab 1fludarabine phosphate 1fludarabine 1exemestane 1epigallocatechin gallate 1durvalumab 1aumolertinib 1atropine sulfate-diphenoxylate hydrochloride drug combination 1Vincristine 1Tamoxifen 1Sodium Chloride 1R-CHOP protocol 1Prednisone 1Pemetrexed 1Omeprazole 1Melphalan 1Loperamide 1Letrozole 1High-Energy Shock Waves 1Gastroscopy 1Etoposide 1Doxorubicin 1Dexamethasone 1Decitabine 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Catechin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Enrolling by invitation × Busulfan × Clear all
NCT05674539 2025-02-10

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3 Enrolling by invitation
200 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡